Evaluating the effect of montelukast tablets on respiratory complications in patients following blunt chest wall trauma: A double-blind, randomized clinical trial.
10.1016/j.cjtee.2022.10.002
- Author:
Soleyman HEYDARI
1
,
2
;
Hadi KHOSHMOHABAT
3
;
Ali Taheri AKERDI
4
;
Fathollah AHMADPOUR
3
;
Shahram PAYDAR
5
Author Information
1. Department of Surgery, Baqiyatallah University of Medical Sciences, Tehran, Iran
2. Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
3. Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
4. Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: ata.110.iran@gmail.com.
5. Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
- Publication Type:Journal Article
- Keywords:
Acute respiratory distress syndrome;
Contusions;
Injuries;
Leukotrienes;
Montelukast
- MeSH:
Humans;
Adolescent;
Thoracic Wall;
Pneumonia;
Wounds, Nonpenetrating;
Thoracic Injuries/drug therapy*;
Lung Injury;
Contusions;
Respiratory Distress Syndrome/etiology*;
Inflammation;
Tablets;
Treatment Outcome
- From:
Chinese Journal of Traumatology
2023;26(2):116-120
- CountryChina
- Language:English
-
Abstract:
PURPOSE:Patients with multiple traumas are at high risk of developing respiratory complications, including pneumonia and acute respiratory distress syndrome. Many pulmonary complications are associated with systemic inflammation and pulmonary neutrophilic infiltration. Leukotriene-receptor antagonists are anti-inflammatory and anti-oxidant drugs subsiding airway inflammation. The present study investigates the effectiveness of montelukast in reducing pulmonary complications among trauma patients.
METHODS:This randomized, double-blind, placebo-control trial was conducted in patients with multiple blunt traumas and evidence of lung contusion detected via CT scan. We excluded patients if they met at least one of the following conditions: < 16 years old, history of cardiopulmonary diseases or positive history of montelukast-induced hypersensitivity reactions. Patients were allocated to the treatment (10 mg of montelukast) or placebo group using permuted block randomization method. The primary measured outcome was the volume of pulmonary contusion at the end of the trial. The secondary outcomes were intensive care unit and hospital length of stay, ventilation days, multi-organ failure, and the in-hospital mortality rate.
RESULTS:In total, 65 eligible patients (treatment = 31, placebo = 34) were included for the final analysis. The treatment group had more pulmonary contusion volume (mean (SD), mm3) at the right (68726.97 (93656.54) vs. 59730.27 (76551.74)) and the left side (67501.71 (91514.04) vs. 46502.21 (80604.21)), higher initial C-reactive peptide level (12.16 (10.58) vs. 10.85 (17.87)) compared to the placebo group, but the differences were not statistically significant (p > 0.05). At the end of the study, the mean (SD) of pulmonary contusion volume (mm3) (right side = 116748.74 (361705.12), left side = 64522.03 (117266.17)) of the treatment group were comparable to that of the placebo group (right side = 40051.26 (64081.56), left side = 25929.12 (47417.13), p = 0.228 and 0.082, respectively). Moreover, both groups have statistically similar hospital (mean (SD), days) (10.87 (9.83) vs. 13.05 (10.12)) and intensive care unit length of stays (mean (SD), days) (7.16 (8.15) vs. 7.82 (7.48)). Of note, the frequency of the in-hospital complications (treatment vs. control group) including acute respiratory distress syndrome (12.9% vs. 8.8%, p = 0.71), pneumonia (19.4% vs. 17.6%, p = 0.85), multi-organ failure (12.9% vs. 17.6%, p = 0.58) and the mortality rate (22.6% vs. 14.7%, p = 0.41) were comparable between the groups.
CONCLUSION:Administrating montelukast has no preventive or therapeutic effects on lung contusion or its complications.
